Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
SOS1-IN-15
Contact us for more batch information
Select Batch
Purity:98.32%
SOS1-IN-15
Catalog No. T73164Cas No. 2793404-47-2
SOS1-IN-15 is an orally active and potent SOS1 inhibitor with potential antitumor activity.SOS1-IN-15 is used in the study of colon cancer.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $148 | In Stock | |
| 5 mg | $372 | In Stock | |
| 10 mg | $662 | In Stock | |
| 25 mg | $1,360 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "SOS1-IN-15"
PLX-4720
T2473918505-84-7
PLX-4720, a potent and selective inhibitor of B-Raf (V600E) with an IC50 of 13 nM, is equally effective against c-Raf-1 (Y340D and Y341D mutations).
- $32
Size
QTY
LY3009120
T68821454682-72-4
LY3009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 values of 44 nM for A-raf, 31-47 nM for B-Raf, and 42 nM for C-Raf in A375 cells. Phase 1.
- $30
Size
QTY
Regorafenib
Cited
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.
- $30
Size
QTY
CitedRegorafenib monohydrate
T1792L1019206-88-2
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.
- $30
Size
QTY
Doramapimod Cited
T6277285983-48-4
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
- $31
Size
QTY
CitedVemurafenib Cited
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- $50
Size
QTY
CitedSorafenib Cited
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
- $27.2
- $34
Size
QTY
CitedGW 441756
T6052504433-23-2
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
- $51
Size
QTY
Sorafenib tosylate Cited
T0093475207-59-1
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
- $37
Size
QTY
CitedDabrafenib Cited
T19031195765-45-7
Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5/0.6 nM) and is ATP-competitive. Dabrafenib exhibits antitumor activity for the treatment of B-RafV600E-mutated melanoma.
- $41
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | SOS1-IN-15 is an orally active and potent SOS1 inhibitor with potential antitumor activity.SOS1-IN-15 is used in the study of colon cancer. |
| Targets&IC50 | KRAS-SOS1:5 nM |
| In vitro | In Mia-paca-2 pancreatic cancer cells, SOS1-IN-15 (0.1 nM-0.1 mM; 72 hours) inhibited cell proliferation with an IC50 of 178 ± 42 nM[1]. |
| In vivo | In BALB/c nude mice bearing Mia-paca-2 pancreatic tumors, SOS1-IN-15 (50 mg/kg; oral administration, daily for 22 days) showed 49% tumor inhibition. No animal mortality and significant difference in the mice’s body weight were observed during the study period[1]. |
| Molecular Weight | 536.548 |
| Formula | C28H27F3N6O2 |
| Cas No. | 2793404-47-2 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||
| Solubility Information | DMSO: 2 mg/mL (3.73 mM), Sonification is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy SOS1-IN-15 | purchase SOS1-IN-15 | SOS1-IN-15 cost | order SOS1-IN-15 | SOS1-IN-15 chemical structure | SOS1-IN-15 in vivo | SOS1-IN-15 in vitro | SOS1-IN-15 formula | SOS1-IN-15 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.